A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Learn more about Alaunos Therapeutics Inc’s (TCRT) stock grades for Value, Growth, Momentum, Estimate Revisions and Quality and determine whether this Biotechnology & Medical Research stock meets your investment needs.
Issac Deleon
| Share Statistics | TCRT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2.3 | $250.6 | 1% |
|
| Shares Out (Mil) | 2.4 | 54.0 | 9% |
|
| Institutional Ownership | 21.6% | 93.1% | 10% |
|
| Float (Mil) | 2.0 | 41.4 | 5% |
|
| Beta | -0.96 | 0.95 | 1% |
|
| Avg Daily Volume (000s) | 3,464 | 720 | 87% |
|
| Price Change (52-week) |
(61.8%) | 49.4% | 13% |
|
| Growth | TCRT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | 44.5% | (10.2%) | 92% |
|
| EPS (5yr) | 47.9% | 15.7% | 92 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (64.1%) | (15.7%) | 3% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | TCRT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $36 | na |
|
| Net Income (TTM) (Mil) | ($4) | ($44) | 34% |
|
| EPS (TTM) | ($1.768) | ($1.600) | 16% |
|
| Operating Cash Flow (TTM) (Mil) | ($3) | ($33) | 28% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $4 | $174 | 5% |
|
| Valuation | TCRT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.54 | 2.41 | 71% |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | TCRT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.3% | na |
|
| Net Margin | na | (73.7%) | na |
|
| ROA | (128.3%) | (47.7%) | 4% |
|
| ROE | (185.9%) | (55.0%) | 4% |
|
| Liabilities to Assets | 57.0% | 29.3% | 50% |
|
| F-Score | 1 | 3 | 1% |
|
Alaunos Therapeutics, Inc. did not pass any screens on 10/1/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors
